Sun Pharmaceutical Industries is currently trading at Rs 820.10, down by 39.55 points or 4.60% from its previous closing of Rs 859.65 on the BSE.
The scrip opened at Rs 853.00 and has touched a high and low of Rs 853.00 and Rs 808.00 respectively. So far 445047 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 1 has touched a 52 week high of Rs 877.40 on 03-Sep-2014 and a 52 week low of Rs 535.55 on 18-Sep-2013.
Last one week high and low of the scrip stood at Rs. 873.30 and Rs. 852.75 respectively. The current market cap of the company is Rs. 170529.28 crore.
The promoters holding in the company stood at 63.65% while Institutions and Non-Institutions held 28.05% and 8.29% respectively.
Sun Pharmaceutical Industries’ manufacturing facility in Halol in Gujarat is undergoing a surprise audit by the US Food and Drug Administration (US FDA). The move may have been triggered by a number of recent recalls from the plant. The plant contributes to around 40% of US sales and around 25% of consolidated profit of the company.
Earlier in May, the company’s another manufacturing facility in Karkhadi, also in Gujarat, had received a warning letter from the US FDA after investigators identified violations of current good manufacturing practice and regulations for finished pharmaceuticals.
Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: